This study provides key clinical evidence for immunotherapy strategies in mTNBC, suggesting that PD-L1-positive patients may benefit from carboplatin combined with nivolumab. It offers valuable insights for the design of subsequent biomarker-driven clinical trials.
Literature Overview
The article titled 'Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial,' published in Nature Communications, systematically investigates the efficacy and safety of carboplatin combined with nivolumab versus carboplatin alone in patients with metastatic triple-negative breast cancer (mTNBC) regardless of PD-L1 status. The study employs a multicenter, open-label, randomized phase II design, with the primary endpoint being progression-free survival (PFS) in the modified intent-to-treat (mITT) population, and focuses on clinical outcomes in the PD-L1-positive subgroup. The research also integrates multi-level biomarkers including ctDNA dynamics, tumor mutational burden (TMB), transcriptomics, and microbiome data, aiming to identify potential predictive factors and advance precision immunotherapy.Background Knowledge
Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype with poor prognosis, accounting for 10–15% of all breast cancers. It is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, limiting targeted therapy options and leaving chemotherapy as the mainstay. Although immune checkpoint inhibitors (ICIs) such as atezolizumab and pembrolizumab have been approved for PD-L1-positive mTNBC, the predictive performance of current biomarkers (e.g., PD-L1, TILs) remains suboptimal, with inconsistencies across different assay platforms (e.g., SP142, 22C3). Additionally, primary or acquired resistance occurs in some patients, and the underlying mechanisms are not fully understood. This study explores whether combining carboplatin—a DNA-damaging agent with immunomodulatory potential—with the PD-1 inhibitor nivolumab can enhance antitumor immune responses, particularly in PD-L1-positive patients, and uses multi-omics analyses to uncover more precise predictive biomarkers such as TMB, ctDNA dynamics, and microbiome functional pathways.
Research Methods and Experiments
The study enrolled 75 treatment-naïve mTNBC patients, randomly assigned to receive either carboplatin plus nivolumab (n=37) or carboplatin monotherapy (n=38). The primary analysis focused on the mITT population (n=62) who had not received prior chemotherapy for metastatic disease. All patients underwent central laboratory PD-L1 testing (SP142 clone), and tumor tissues were collected for OncoPanel NGS, whole-exome sequencing (WES), and transcriptomic profiling. Plasma samples were used for ctDNA and serum thymidine kinase activity (TKa) analysis, and fecal samples were analyzed via 16S rRNA sequencing to assess the gut microbiome. Efficacy endpoints included PFS, OS, and ORR, with safety evaluated using CTCAE v4.0. Associations between multi-omics data and clinical outcomes were analyzed using Cox regression, GSEA, CART, and other methods.Key Conclusions and Perspectives
Research Significance and Prospects
This study underscores the importance of biomarker stratification in mTNBC immunotherapy, where PD-L1 status, TMB, and ctDNA dynamics collectively form a multidimensional predictive model to identify patients most likely to benefit from ICI-chemotherapy combinations. Future prospective trials based on PD-L1 and TMB are warranted to validate the clinical benefit of such combinations. Early ctDNA dynamics can serve as a pharmacodynamic biomarker for interim analyses or adaptive trial designs, accelerating drug development. Moreover, the discovery of microbiome functional pathways—such as the urea cycle—suggests that dietary or probiotic interventions could modulate treatment response, opening new avenues for adjuvant strategies.
Conclusion
This study systematically evaluates the efficacy and safety of carboplatin plus nivolumab in mTNBC. Although no significant PFS benefit was observed in the overall population, a trend toward clinical improvement was noted in PD-L1-positive patients. By integrating multi-omics data—including TMB, ctDNA dynamics, transcriptomics, and microbiome—the study reveals several potential predictive and prognostic biomarkers, particularly early ctDNA clearance and urea cycle pathway activity, offering new perspectives for personalized therapy. From bench to bedside, these findings support the future use of multidimensional biomarker strategies in mTNBC to optimize patient selection for immunotherapy-chemotherapy combinations. Additionally, serum TKa and microbiome functional profiles may serve as non-invasive monitoring tools to assess treatment response and inform intervention timing. This study lays a critical foundation for precision immunotherapy in mTNBC, advancing the field from a 'one-size-fits-all' approach toward dynamic, multi-layered personalized management, with the potential to improve long-term outcomes in this challenging disease.
